Year None20262025202420232022202120202019201820172016 March 18, 2026 Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026 Go to February 18, 2026 Medicenna Therapeutics Announces Participation in Upcoming Conferences Go to February 13, 2026 Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update Go to February 13, 2026 Medicenna Announces Changes to Board Composition Go to January 15, 2026 Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook Go to
March 18, 2026 Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026 Go to
February 13, 2026 Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update Go to
